DOCSLIB.ORG

GIP-Gip2019ces-1UP 1..179

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

CANCERS OF THE ESOPHAGUS AND STOMACH 2 Oral Abstract Session, Thu, 2:15 PM-3:45 PM and Poster Session (Board #D12), Thu, 11:30 AM-1:00 PM and 5:30 PM-6:30 PM Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. Takashi Kojima, Kei Muro, Eric Francois, Chih-Hung Hsu, Toshikazu Moriwaki, Sung-Bae Kim, Se-Hoon Lee, Jaafar Bennouna, Ken Kato, Shen Lin, Shi-Qui Qin, Paula Ferreira, Toshihiko Doi, Antoine Adenis, Peter C. Enzinger, Manish A. Shah, Ruixue Wang, Pooja Bhagia, S. Peter Kang, Jean-Philippe Metges; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan; Lacassagne Anticancer Center, Nice, France; National Taiwan University Hospital, Taipei, Taiwan; University of Tsukuba, Tsukuba, Japan; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; University Hospital of Nantes, Nantes, France; Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; Beijing Cancer Hospital, Beijing, China; PLA Cancer Centre of Nanjing Bayi Hospital, Nanjing, China; Instituto Portuguesˆ de Oncologia Porto, Porto, Portugal; National Cancer Center Hospital East, Chiba, Japan; Centre Oscar Lambret, Lille, France; Dana-Farber Cancer Institute, Boston, MA; Weill Cornell Medicine/ New York Presbyterian Hospital, New York, NY; MSD China, Beijing, China; Merck, Kenilworth, NJ; Merck & Co., Inc., Kenilworth, NJ; Oncology & Haematology Institute, Brest University Hospital, Brest, France Background: Patients with advanced esophageal cancer after first-line chemotherapy (chemo) have a poor prognosis and limited treatment options. We present results of the phase 3 KEYNOTE- 181 study of pembrolizumab vs investigator’s choice chemo as second-line therapy for patients (pts) with advanced/metastatic squamous cell carcinoma (SCC) and adenocarcinoma of the esophagus or Siewert type I adenocarcinoma of the EGJ (NCT02564263). Methods: Eligible pts were randomized 1:1 to pembrolizumab 200 mg Q3W for up to 2 years or investigator’s choice chemo of paclitaxel, docetaxel, or irinotecan. Randomization was stratified by histology (SCC vs adenocarcinoma) and region (Asia vs rest of world). Primary end points were OS in the SCC, PD-L1 combined positive score (CPS) $10, and ITT populations. Results: 628 pts were randomized including 401 with SCC, and 222 with CPS $10. As of October 15, 2018, the median follow-up was 7.1 mo (pembrolizumab) vs 6.9 mo (chemo). Pembrolizumab was superior to chemo for OS in CPS $10 (N=222; median 9.3 vs 6.7 mo; HR 0.69; 95% CI 0.52-0.93; P=0.0074). The 12-mo OS rate in pts with CPS $10 was 43% vs 20%. There was clinically meaningful improvement in OS with pembrolizumab vs chemo in pts with SCC, but this was not statistically significant per prespecified boundaries (N=401; 8.2 mo vs 7.1 mo; HR 0.78; 95% CI 0.63-0.96; P=0.0095). In the ITT population, while directionally favorable, the difference in OS was not statistically significant (N=628; 7.1 mo vs 7.1 mo; HR 0.89; 95% CI 0.75-1.05; P=0.0560). Fewer pts had any-grade (64% vs 86%) or grade 3-5 (18% vs 41%) drug-related AEs with pembrolizumab vs chemo. Conclusion: Pembrolizumab significantly improved OS compared with chemo as second-line therapy for advanced esophageal cancer with PD-L1 CPS $10, with a more favorable safety profile. These data support pembroli- zumab as a new second-line standard of care for esophageal cancer with PD-L1 CPS $10. The phase 3 KEYNOTE-590 study of pembrolizumab plus chemo as first-line therapy for advanced esoph- ageal cancer is ongoing (NCT03189719). Clinical trial information: NCT02564263. © 2019 American Society of Clinical Oncology. Visit gicasym.org and search by abstract for disclosure information. CANCERS OF THE ESOPHAGUS AND STOMACH 3 Oral Abstract Session, Thu, 2:15 PM-3:45 PM and Poster Session (Board #D13), Thu, 11:30 AM-1:00 PM and 5:30 PM-6:30 PM Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric cancer (mGC) with or without prior gastrectomy: Results from a phase III study (TAGS). David H. Ilson, Aliaksandr Prokharau, Hendrik-Tobias Arkenau, Michele Ghidini, Kazumasa Fujitani, Eric Van Cutsem, Peter C. Thuss-Patience, Giordano D. Beretta, Wasat Mansoor, Edvard Zhavrid, Maria Alsina, Ben George, Daniel V.T. Catenacci, Robert E. Winkler, Lukas Makris, Toshihiko Doi, Kohei Shitara; Memorial Sloan Kettering Cancer Center, New York, NY; Minsk City Clinical Oncology Dispensary, Minsk, Belarus; Sarah Cannon Research Institute and University College London, London, United Kingdom; Azienda Ospedaliera di Cremona, Cremona, Italy; Osaka General Medical Center, Osaka, Japan; University Hospitals and KU Leuven, Leuven, Belgium; Charit´e – Universit¨atsmedizin Berlin, Berlin, Germany; Humanitas Gavazzeni, Bergamo, Italy; The Christie NHS Foundation Trust Hospital, Manchester, United Kingdom; Alexandrov National Cancer Centre of Belarus, Minsk, Belarus; Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain; Medical College of Wisconsin, Milwaukee, WI; University of Chicago Medical Center and Biological Sciences, Chicago, IL; Taiho Oncology, Inc., Princeton, NJ; Stathmi, Inc., New Hope, PA; National Cancer Center Hospital East, Chiba, Japan Background: The phase 3 study TAGS demonstrated that the novel oral therapy FTD/TPI (TAS-102) represents an effective treatment option with a manageable safety profile for pts with heavily pretreated mGC. In an earlier single-arm Japanese phase 2 trial in mGC, no differences were found in the pharmacokinetics of either FTD or TPI in pts with or without prior gastrectomy. We evaluated the efficacy and safety of FTD/TPI in pts with or without prior gastrectomy within the TAGS study. Methods: In this global phase 3 study of adult pts with mGC who had received $ 2 prior regimens of chemotherapy, pts were randomized 2:1 to receive FTD/TPI (35 mg/m2 BID on days 1–5 and 8–12 of each 28-day cycle) or placebo, plus best supportive care. We performed a preplanned analysis of efficacy and safety endpoints in pt subgroups with or without prior gastrectomy. Results: Of 507 randomized pts, 221 (44%) had a prior gastrectomy (FTD/TPI, 147/337; placebo, 74/170). Baseline pt characteristics were balanced across pt subgroups. FTD/TPI prolonged survival versus placebo regardless of gastrectomy (table). The frequency of neutropenia/leukopenia appeared to be higher among FTD/TPI-treated pts with vs without gastrectomy, but this did not result in more treatment discontinuations (table). Conclusions: In the TAGS study, subgroup analysis demonstrated that FTD/TPI is an effective treatment option with a manageable safety profile for pts with heavily pretreated mGC, regardless of prior gastrectomy. Clinical trial information: NCT02500043. Gastrectomy No gastrectomy FTD/TPI Placebo FTD/TPI Placebo ITT population, n 147 74 190 96 Median OS (95% CI), mo 6.0 (4.6–7.0) 3.4 (2.7–3.8) 5.6 (4.6–6.2) 3.8 (3.1–5.9) HR (95% CI) 0.57 (0.41–0.79) 0.80 (0.60–1.06) OS rate (95% CI), % 6mo 50 (41–58) 24 (15–35) 44 (37–52) 39 (30–49) 12 mo 20 (12–28) 9 (3–19) 22 (16–30) 16 (8–26) Safety population, n 145 73 190 95 Grade ‡3 AEs of any cause, % Any 84 60 76 56 Most commona Neutropenia 28 0 19 0 Anemia 21 4 17 11 Decreased neutrophil count 17 0 7 0 Leukopenia 10 0 4 0 Fatigue 2 5 11 6 AEs of any grade or cause, % Leading to dosing modification 65 21 53 23 Leading to treatment discontinuation 10 16 15 17 aOccurring in $10% of pts in any group © 2019 American Society of Clinical Oncology. Visit gicasym.org and search by abstract for disclosure information. CANCERS OF THE ESOPHAGUS AND STOMACH 4 Oral Abstract Session, Thu, 2:15 PM-3:45 PM and Poster Session (Board #D14), Thu, 11:30 AM-1:00 PM and 5:30 PM-6:30 PM A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1). Manish A. Shah, Eduardo Patricio Yanez Ruiz, Gyorgy Bodoky, Alexander Starodub, David Cunningham, Desmond Yip, Zev A. Wainberg, Johanna C. Bendell, Dung Thai, Pankaj Bhargava, Jaffer A. Ajani; Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY; University de la Frontera, Temuco, Chile; Szent L´aszl´o Teaching Hospital, Budapest, Hungary; Parkview Comprehensive Cancer Institute/Parkview Health, Fort Wayne, IN; The Royal Marsden NHS Foundation Trust, Sutton and London Hospital, Sutton, United Kingdom; ANU Medical School, Australian National University, Canberra, Australia; University of California Los Angeles School of Medicine, Los Angeles, CA; Sarah Cannon Research Institute/ Tennessee Oncology, Nashville, TN; Gilead Sciences, Inc., Foster City, CA; University of Texas MD Anderson Cancer Center, Houston, TX Background: Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9, an extracellular enzyme involved in matrix remodeling, tumor growth, and metastasis. A phase I/Ib study of mFOLFOX6 + ADX revealed encouraging antitumor activity in patients (pts) with gastric or gastroesophageal junction (GEJ) adenocarcinoma (median first-line, progression-free survival [PFS] of 9.9 months). Methods: This phase 3, randomized, double-blind, multicenter study investigated the efficacy and safety of mFOLFOX6 with/without ADX in pts with untreated HER2-negative gastric or GEJ adenocarcinoma. Randomization was 1:1 to mFOLFOX6 + ADX or mFOLFOX6 + placebo (PBO).
Recommended publications
  • Japanese Delegation of Athletics Team for Doha,Qatar 2019 27 SEP-06 OCT

    Japanese Delegation of Athletics Team for Doha,Qatar 2019 27 SEP-06 OCT

    Japanese Delegation of Athletics Team For Doha,Qatar 2019 27 SEP-06 OCT IAAF World Championships in Athletics-Doha,Qatar 第 17 回 IAAF 世界陸上競技選手権大会 （ カタ ー ル ・ドー ハ ） ❶ Hirooki ARAI(L)& Kai KOBAYASHI(R) Play Back London 2017 ［プレイバック・ロンドン大会2017］ 前回の2017年ロンドン大会では男子50kmW勢が躍動。 荒井広宙が２位、小林快が3位とダブル表彰台に上り、 丸尾知司も５位に入りました。また、男子４×100ｍＲ も３位に入り、世界選手権では初のメダルを獲得。また、 サニブラウン アブデルハキームは男子100ｍで準決勝、 200ｍでは決勝に進出（７位）。日本はメダル３、入賞２ の成績を収めました。 ❷ Men’s 4×100m Relay ❸ Satoshi MARUO ❹ Abdul Hakim SANIBROWN Japanese Medalists & Prizewinners in London 2017 Silver Athlete Record Men 50kmW Hirooki ARAI ❶Left 3.41.17 Bronze Men 50kmW Kai KOBAYASHI ❶Right 3.41.19 S.TADA,S.IIZUKA, Men 4×100mR 38.04 Y.KIRYU,K.FUJIMITSU❷ 5th Men 50kmW Satoshi MARUO❸ 3.43.03 7th Men 200m Abdul Hakim SANIBROWN❹ 20.63 02 Message［メッセージ］ thletes aiming at the top of the world will be gathering in the blazing city Doha. The IAAF World Athletics Championships Doha 2019 is a great stageA for you to challenge the “power and skill” of the world, and it has an important meaning as a prelude to 2020 Tokyo Olympic Games which is quickly approaching. Expand your athletic ability you have gained through competition experiences and years of hard training here in Doha and make a huge step towards the grand stage. Along with your athletic ability, human quality is also very important. Athletics is an individual sport except for relays, but it is necessary to have Team JAPAN awareness. The consciousness of competing as a team will also enhance your human quality, and that rise helps to improve individual competitiveness. For athletes and staff, I ask you to unite by respecting each other, and have the spirit of “One for All, All for One”.
  • 155-L Page CHAPTER XII the 123D Division

    155-L Page CHAPTER XII the 123D Division

    N SI 55 U.S. Army Forces Far East. Military History Section. Record of Opera- tions Against Soviet Russia on Northern and Western Fronts of Manchuria, and in Northern Korea (August 1945). Japanese monograph no. 155. 1950. Distributed by the Office of the Chief of Military History, Departmen t of the Army. SAI ACCESS NO r77 A N Ju:i 2 ZQO ACCESSION NO -~iili~asi~w(i~I1786 7 '' ~r9 r k-':: ~a~ -jgy "'; :r' i.i 'i JAPANESE MONOGRAPH NO. 155 Ate.1 +++"-.i ti.,<a.. .. , i4,e NO su w..w..v- RECORD OF OPERATIONS AGAINST SO VIET RUSSIA ON NORTHERN AND WESTEF:N FRONTS OF MANCHURIA, AND IN NORTHERN KOREA (AUGUST 1945) PREPARED BY- MILITARY HISTORY SECTION HEADQUARTERS, ARMY FORCES FAR EAST DISTRIBUTED BY OFFICE OF THE CHIEF OF MILITARY HISTORY DEPARTMENT OF THE ARMY This monograph may not be reproduced without the permission of the Office Chief of Militsry History Monograph No. 155 Editor's Preface This is the last in a series of three monographs' covering Japanese military activities in Manchuria from January 1943 to the end of WVorld War II hostilities, prepared by former commanders and staff officers of the Kwantung Army. The first (No. 138) deals with Kwantung Arm's wartime vigil throughout Manchuria in prepa- ration for operations. The second (No. 154) deals with actual military operations against Soviet forces on the eastern front. This monograph, No. 155, covers operations in the northern and western parts of Manchuria and also in northern Korea. Like No. 154, this monograph is actually a collection of closely related sub-monographs, each a separate--but by no means complete--study in itself.
  • HEEL and TOE ONLINE the Official

    HEEL and TOE ONLINE the Official

    HEEL AND TOE ONLINE The official organ of the Victorian Race Walking Club 2014/2015 Number 47 25 August 2015 VRWC Preferred Supplier of Shoes, clothes and sporting accessories. Address: RUNNERS WORLD, 598 High Street, East Kew, Victoria (Melways 45 G4) Telephone: 03 9817 3503 Hours: Monday to Friday: 9:30am to 5:30pm Saturday: 9:00am to 3:00pm Website: http://www.runnersworld.com.au Facebook: http://www.facebook.com/pages/Runners-World/235649459888840 WALKER OF THE WEEK A quick word before going to my Walker of the Week. Since I am in China at the moment, I am locked out of quite a few of the resources from which I put together my weekly newsletter – facebook, twitter, dropbox, all google facilities and various other normally inoffensive websites, not to mention my own gmail account. So if your results aren't there or I haven't responded to your email, it may be that I was just not able to pick them up. Email me via [email protected] and I can rectify in next week's newsletter. And now onto business! This weeks' Walker of the Week goes to 23 year old Australian representative Dane Bird-Smith. Racing in the IAAF World Championship 20km race on Sunday morning, he overcome a mid-race bingle and an upset stomach to finish eighth, confirming his status as the next big thing in Australian walking. Dane was among a group of several walkers who crashed over a flower bed in the middle of the course at the 12km mark but he was able to regroup to claim eighth spot in a time of 1:21:37, three places better than on his world titles debut two years ago in Moscow.
  • Becoming the World's Most Competitive Restaurant Service Company

    Becoming the World's Most Competitive Restaurant Service Company

    BECOMING THE WORLD'S MOST COMPETITIVE RESTAURANT SERVICE COMPANY Year Ended February 29, 2016 CONTENTS 02 Financial and Non-financial Highlights 04 Message from the President and CEO 05 Business Strategy 08 Our Brands 10 Corporate Governance 12 Management’s Discussion and Analysis 14 Consolidated Financial Statements 17 Corporate Data Stock Code : 3387 What is create restaurants group? BASIC PHILOSOPHY CREATIVITY Since its foundation in 1999, create restaurants group has planned, developed, and operated restaurants in a wide variety of formats ranging from casual food courts and izakaya to restaurants offering a more formal dining experience. All these restaurants are attuned to SPEED CHALLENGE the characteristics of their locations and customer demographics, and the entire business is directly managed in accordance with an original strategy based on our fundamental philosophy of speed, creativity, and the pursuit of new challenges. Central to the mission of the create New York restaurants group is a concerted effort to earn the enduring trust of JAPAN our customers and develop new restaurant locations by drawing on SHANGHAI a wealth of experience and knowledge accumulated over the years. TAIWAN We will continue to expand our presence in Japan and abroad in the HONG KONG coming years. 197brands SLOGAN * SINGAPORE Becoming the world’s most competitive restaurant service company restaurants * Number of restaurants includes795 licensed businesses, franchised stores and overseas joint ventures. create restaurants inc. SFP Dining Co., Ltd. KR
  • 129Th Annual Meeting Monday, October 4, 2004 Abstracts

    129Th Annual Meeting Monday, October 4, 2004 Abstracts

    ENG showed acute and chronic motor neuron damage and 129th Annual Meeting sensitive axonal neuropathy, confirmed by muscle and nerve biopsies. Brain MRI revealed cerebellar atrophy. MEP, EEG, Monday, October 4, 2004 and fundoscopy were normal. ␤-HEXB activity was unde- tectable in leukocytes. Molecular genetic studies are in Abstracts: Poster Sessions progress. ␤-HEXB deficiency should be considered in differ- ential diagnosis of juvenile MND, also for prognostic rea- sons: indeed, studies with animal models indicate substrate deprivation as a potential treatment for ␤-HEXB deficiency. FUNCTIONAL GENETICS WALKING TOUR 1. Transgenic Mouse Model for the Human GLUT1- 3. Effect of Tau and ApoE Genotypes on Age at Deficiency Syndrome Onset and Age at Death in Progressive Supranuclear Charles Heilig, Vasilis Koliatsos, Jehuda Sepkuty, Palsy Kathleen Heilig, Shenglin Chen, Minghui Xiang, Yasuhiko Baba, Yoshio Tsuboi, Keith A. Josephs, Donald Price, James Fox, Martin Pomper, David Borchelt, Natalie Cookson, Zbigniew K. Wszolek, and and Alena Savonenko; Baltimore, MD Dennis W. Dickson; Jacksonville, FL; Fukuoka, Japan; and The human GLUT1-deficiency syndrome (GLUT1DS) is Rochester, MN characterized by mutations that decrease GLUT1 expression OBJECTIVE: To assess the effect of tau and ApoE geno- or produce dysfunctional GLUT1 protein, resulting in re- types on age at onset (AAO) and age at death (AAD) of duced glucose transport across the blood-brain barrier. Af- pathologically confirmed progressive supranuclear palsy fected individuals appear normal at birth, but have hypogly- (PSP). METHODS: Fifty-two pathologically proven PSP corrachia, and eventually exhibit developmental delay, cases that lacked any other prominent neurodegenerative dis- acquired microcephaly, recurrent seizures, abnormal coordi- order were taken from the PSP Brain Bank and enrolled.
  • Prog-Web.Pdf

    Prog-Web.Pdf

    Programme Programme MARS - MAI ‘16 EXPOSITION MARS - MAI 2016 RÉTROSPECTIVE GUS VAN SANT RÉTROSPECTIVES HOU HSIAO-HSIEN Jean gabin Raoul ruiz Pierre richard MichÈle rosier Carte blanche à jean-michel alberola cinematheque.fr La Cinematheque-Parution MDE-012016 19/01/16 15:12 Page1 www.maisondesetatsunis.com POUR Vos voyages à PORTLAND La Maison des Etats-Unis ! Love Portland - 1670 €* Séjour de 7 j. / 5 n. Vols internationaux, hôtel*** Partez assisté d’une équipe de spécialistes qui fera de votre voyage un moment inoubliable. Retrouvez l’ensemble de nos offres www.maisondesetatsunis.com 3, rue Cassette Paris 6ème Tél. 01 53 63 13 43 [email protected] Du lundi au samedi de 10h à 19h. Prix à partir de, soumis à conditions Copyright Torsten Kjellstrand www.travelportland.com Gerry ÉDITORIAL Après Martin Scorsese, c’est à Gus Van Sant que la Cinémathèque française consacre une grande exposition et une rétrospective intégrale. Nourri de modernité euro- péenne, figure du cinéma américain indépendant dans les années 90, à l’instar d’un Jim Jarmush pour la décennie précédente, le cinéaste de Portland, Oregon est un authentique plasticien. Nous sommes heureux de montrer pour la première fois en France ses travaux de photographe et de peintre, et d’établir ainsi des correspon- dances avec ses films. Grand inventeur de dispositifs cinématographiques Elephant( , pour citer le plus connu de ses théorèmes), Gus Van Sant est aussi avide d’expériences commerciales, menées au cœur même de l’industrie (Prête-à-tout, Psychose, Will Hunting ou À la recherche de Forrester), et pour lesquelles il peut déployer toute sa plasticité d’auteur très américain, à la fois modeste et déterminé.
  • Abstracts Pp. 152-450

    Abstracts Pp. 152-450

    Kingship Ideology in Sino-Tibetan Diplomacy during the VII-IX centuries Emanuela Garatti In this paper I would like to approach the question of the btsan-po’s figure and his role in the international exchanges like embassies, peace agreements and matrimonial alliances concluded between the Tibetan and the Tang during the Tibetan Empire. In order to do that, I examine some passages of Tibetan and Chinese sources. Tibetan ancient documents, like PT 1287, the PT 1288, the IOL Tib j 750 and the text of the Sino-Tibetan treaty of 821/822. For the Chinese sources I used the encyclopaedia Cefu yuangui which has never been extensively used in the study of the Tibetan ancient history. Concerning the embassies one can see that they are dispatched with important gifts when the btsan-po want to present a request. Those are registered as tribute (ch. chaogong) by the Chinese authors but one can assume, analysing the dates of embassies that the Tibetan emissaries are sent to the court with presents only when they had to present a specific request from the Tibetan emperor. Moreover, the btsan-po is willing to accept the diplomatic codes but refuses all attempt of submission from the Chinese authorities like the “fish-bag” (ch. yudai) proposed to the Tibetan ambassadors as a normal gift. For the treaties, the texts of these agreements show the evolution of the position of the btsan-po towards the Chinese court and the international diplomacy: the firsts pacts see the dominant position of Tang court over the btsan-po’s delegation.
  • Kobe University Repository : Thesis

    Kobe University Repository : Thesis

    Kobe University Repository : Thesis Portugal's 'Estado Novo' Diplomatic Relations with Japan During the 学位論文題目 Second World War(第二次世界大戦間のポルトガルの「エスタド・ Title ノヴォ」と対日外交) 氏名 SOEIRO SIMOES DEBORA CATARINA Author 専攻分野 博士（政治学） Degree 学位授与の日付 2019-03-25 Date of Degree 公開日 2020-03-01 Date of Publication 資源タイプ Thesis or Dissertation / 学位論文 Resource Type 報告番号 甲第7394号 Report Number 権利 Rights JaLCDOI URL http://www.lib.kobe-u.ac.jp/handle_kernel/D1007394 ※当コンテンツは神戸大学の学術成果です。無断複製・不正使用等を禁じます。著作権法で認められている範囲内で、適切にご利用ください。 PDF issue: 2021-10-08 博士学位論文 論文題目 Portugal’s ‘Estado Novo’ Diplomatic Relations with Japan During the Second World War (第二次世界大戦間のポルトガルの「エスタド・ノヴォ」と対日外交) 神戸大学大学院法学研究科 専攻：政治学専攻 指導教授：簑原俊洋 学籍番号：141J035J 氏名：Débora Catarina Soeiro Simões 提出年月日： 2019 年 1 月 10 日 Abstract Portugal’s strategic dogma to survive the war with its colonial empire intact was easy to explain, but strenuous to implement: to publicly maintain a strict neutrality, but when inevitable to collaborate to protect its interests, thus the term collaborating neutrality. In reality this demanded a cautious and skillful use of hedging. Juggling the interests of the several actors was complex and sometimes out of the control of Portuguese authorities. Portuguese and Japanese interests collide in the Asia theater in Macau and East Timor. Both territories of strategic importance to Japan: the former as a espionage center and the latter as a stepping stone to Australia. In 1940, having Macau surrounded, Japan clearly states its intention to pressure Macau to obtain oil concessions in Timor. In turn, this precipitated a policy of appeasement on two fronts: in Macau, Portugal must cede part of its sovereignty in Macau, allowing Japanese a broad spectrum of freedoms; and in Timor, a technical agreement establishing an air service between Palao and Dilli is signed.
  • Jam-Yang-Shay-Pa's Decisive Analysis of Dharmakīrti's

    Jam-Yang-Shay-Pa's Decisive Analysis of Dharmakīrti's

    WHY DID DHARMAKĪRTI WRITE THE COMMENTARY? Jam-yang-shay-pa’s Decisive Analysis of Dharmakīrti’s “Commentary on Valid Cognition” Introduction 1 Hiroshi Nemoto In collaboration with Lo-sang-gyal-tshan Edited by Jeffrey Hopkins UMA INSTITUTE FOR TIBETAN STUDIES Why did Dharmakīrti Write the Commentary? Website for UMA Institute for Tibetan Studies (Union of the Modern and the Ancient: gsar rnying zung `jug khang): uma- tibet.org. UMA stands for “Union of the Modern and the Ancient” and means “Middle Way” in Tibetan. UMA is a non-profit 501(c)3 organization. Why did Dharmakīrti Write the Commentary? Jam-yang-shay-pa’s Decisive Analysis of Dharmakīrti’s “Commentary on Valid Cognition”: Introduction 1 Hiroshi Nemoto Edited by Jeffrey Hopkins UMA Institute for Tibetan Studies uma-tibet.org Expanding Wisdom and Compassion UMA Great Books Translation Project Supported by generous grants from the Yeshe Khorlo Foundation the Pierre and Pamela Omidyar Fund the Silicon Valley Community Foundation and a bequest from Daniel E. Perdue Translating texts from the heritage of Tibetan and Inner Asian Buddhist systems, the project focuses on the study and contemplation of Great Indian Books and Tibetan commentaries from the Go-mang College syllabus as well as a related theme on the fundamental innate mind of clear light in Tantric traditions. A feature of the Project is the usage of consistent vocabulary and format throughout the translations. Publications are available online without cost under a Creative Commons License with the understanding that downloaded mate- rial must be distributed for free: http://uma-tibet.org. UMA stands for Union of the Modern and the Ancient (gsar rnying zung ’jug khang).
  • Race Walking Judges in Olympic Games 1908-2012

    Race Walking Judges in Olympic Games 1908-2012

    IAAF Race Walking Committee Members 1935-2015 The Council of the IAAF at a meeting In Berlin 1935 decided to appoint a special commission to study the rules of walking as well as organization questions in different countries with regard to walking. At the same time the answers to the circular letter sent out by the IAAF office concerning the Olympic walking races were to be studied by the commission which met in Paris 1.2.1936. 1935 Committee for 'Walking': Jean Genet, (FRA), Chairman. 1947 Walking Commission: Fred Blackmore, (GBR) President Ernest Holt, (GBR) Secretary Francis Guilleux (FRA) Giorgio Oberweger (ITA). B. Kopal (CZE). A. Larsen (NOR). Eric G. Linde (SWE) 1951 Walking Commission. Fred Blackmore, (GBR) President Ernest Holt, (GBR) Secretary Francis Guilleux (FRA) Bela Fehervari (HUN) Bruno Zauli, (ITA) A. M. Hagen (NOR) Eric G. Linde (SWE) Armando Libotte (SUI) 1952 Walking Commission. Fred Blackmore, (GBR) President Donald Pain, (GBR) Hon. Secretary, Francis Guilleux (FRA) Bela Fehervari (HUN) Giorgio Oberweger (ITA). A. M. Hagen (NOR) I. lonescu (ROM) Eric G. Linde (SWE) Armando Libotte (SUI) Nicolai Kalinin (USSR) 1956 Walking Commission Giorgio Oberweger, (ITA) President Donald Pain, (GBR) Hon. Secretary, Hubert Sulak (TCH) Francis Guilleux (FRA) Harold Whitlock (GBR) Bela Fehervari (HUN) A. M. Hagen (NOR) I. lonescu (ROM) Eric G. Linde (SWE) Armando Libotte (SUI) Nicolai Kalinin (USSR) 1960 Walking Commission Giorgio Oberweger, (ITA) President Donald Pain, (GBR) Hon. Secretary, Bela Fehervari (HUN) Francis Guilleux (FRA) A. M. Hagen (NOR) I. lonescu (ROM) Eric G. Linde (SWE) Armando Libotte (SUI) Hubert Sulak (CZE) Peter Stepanenko (U.S.S.R) Harold Whitlock (GBR) 1964 WALKING COMMISSION Giorgio Oberweger, (ITA) President Donald Pain, (GBR) Hon.
  • Under First Recruitment of FY 2017-2018 Program

    Under First Recruitment of FY 2017-2018 Program

    List of Fellows Selected through Open Recruitment in Japan The following list includes the names of the selected fellows, their host researchers and research themes under the 1st recruitment of FY 2017-2018 JSPS Postdoctoral Fellowship for Research in Japan (Standard). Under this recruitment, 1221 applications were received, among which 124 fellowships were awarded. Notification of the selection results will be made in writing through the head of the applying institution in the middle of January, 2017. An award letter will be sent to the successful candidates. Unsuccessful candidates are not directly notified of their selection results. However, applicants (host researchers) can see their approximate ranking among all the applications through the JSPS Electronic Application System. Individual requests for selection results are not accepted. Fellow Nationality Host Researcher Host Institution Research Theme Family Name First Name Middle Name ABDUL SAMAD Yarjan PAKISTAN Atsuo YAMADA The University of Tokyo Application of three-dimensional graphene structure to energy storage devices ABOLIMITI Yimingaji CHINA Keiichi MAEDA Kyoto University Binary evoluton study for gravitational wave sources, supernovae and high energy objects ADJOU Paul Franck BENIN Xuenan XUAN Obihiro University of Agriculture Genomic survey and preventive measures of bovine tick-borne protozoan diseases in Southeast MOUMOUNI and Veterinary Medicine Asia AGATHOKLEOUS Evgenios CYPRUS Mitsutoshi KITAO Forestry and Forest Products Promoting abiotic stress tolerance of container-grown
  • Lung Cancer—Non-Small Cell Metastatic

    Lung Cancer—Non-Small Cell Metastatic

    LUNG CANCER—NON-SMALL CELL METASTATIC 9500 Oral Abstract Session, Fri, 8:00 AM-11:00 AM Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. Suresh S. Ramalingam, Tudor Eliade Ciuleanu, Adam Pluzanski, Jong-Seok Lee, Michael Schenker, Reyes Bernabe Caro, Ki Hyeong Lee, Bogdan Zurawski, Clarisse Audigier-Valette, Mariano Provencio, Helena Linardou, Sang-We Kim, Hossein Borghaei, Matthew David Hellmann, Kenneth John O’Byrne, Luis G. Paz-Ares, Martin Reck, Faith Ellen Nathan, Julie R. Brahmer; Winship Cancer Institute, Emory University, Atlanta, GA; Institutul oncologic Orif Dr Ion Chiricuta and UNF Iulia Hatieganu, Cluj Napoca, Romania; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Seoul National University Bundang Hospital, Seongnam, South Korea; SF. Nectarie Oncology Center, Craiova, Romania; Hospital Universitario Virgen Del Rocio, Seville, Spain; Chungbuk National Uni- versity Hospital, Cheongju, Chungbuk, South Korea; Ambulatorium Chemioterapii, Bydgoszcz, Poland; Hopitalˆ Sainte Musse, Toulon, France; Hosp. Univ. Puerta de Hierro, Madrid, Spain; Metropolitan Hospital, Athens, Greece; Asan Medical Center, Seoul, Korea, Republic of (South); Fox Chase Cancer Center, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Princess Alexandra Hospital, Brisbane, Australia; Hospital Universitario 12 de Octubre, CNIO, Universidad Complutense & CiberOnc, Madrid, Spain; Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; Bristol-Myers Squibb, Princeton, NJ; Sidney Kimmel Com- prehensive Cancer Center at Johns Hopkins, Baltimore, MD Background: In the phase 3 CheckMate 227 Part 1 (NCT02477826; minimum follow-up, 29.3 mo), 1L NIVO + IPI significantly improved overall survival (OS) vs chemo in treatment-naive patients (pts) with aNSCLC and tumor PD-L1 expression $ 1% (primary analysis) or , 1% (pre-specified descriptive analysis).